基于LC-MRM-MS的血清载脂蛋白(a)候选参考测量程序的开发
研究开发了基于质谱的候选参考测量程序(cRMP),采用自下而上定量蛋白质组学靶向3种蛋白型肽段,用于血清载脂蛋白(a)检测的标准化。该方法经ISO 15193初步验证,定量不受apo(a)大小多态性影响,线性范围3.8至456 nmol/L,定量下限3.8 nmol/L,平均实验室内不精密度为8.9%、11.9%和12.8%。
要点
- 该cRMP靶向3种蛋白型肽段,定量不受apo(a)大小多态性影响。
- 线性范围3.8至456 nmol/L,定量下限3.8 nmol/L。
- 平均实验室内不精密度为8.9%、11.9%和12.8%。
核心结论
- 开发了稳健、不依赖抗体的基于质谱的cRMP,可作为高阶RMP及apo(a)溯源链和未来RMS的重要组成部分。
- 该cRMP符合预设分析性能规范,有望成为SI可溯源的基于质谱的apo(a) RMS中的RMP候选。
研究设计与样本
- 采用自下而上定量蛋白质组学靶向3种蛋白型肽段开发基于质谱的cRMP。
- 依据ISO 15193使用单一基于人血清、可溯源至原WHO-IFCC RMS的校准品进行初步验证。
主要发现
- 血清apo(a)定量设计上独立于其大小多态性,线性范围3.8至456 nmol/L。
- 使用肽段LFLEPTQADIALLK时apo(a)定量下限为3.8 nmol/L。
- 肽段GISSTVTGR和TPENYPNAGLTR的肽间一致性Pearson R分别为0.987和0.984。
- 方法比较显示良好对应,LFLEPTQADIALLK、GISSTVTGR和TPENYPNAGLTR的斜率分别为0.977、1.033和1.085。
- cRMP对3种肽段的平均实验室内不精密度分别为8.9%、11.9%和12.8%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Medical results generated by European CE Marking for In Vitro Diagnostic or in-house tests should be traceable to higher order reference measurement systems (RMS), such as International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)-endorsed reference measurement procedures (RMPs) and reference materials. Currently, serum apolipoprotein (a) [apo(a)] is recognized as a novel risk factor for cardiovascular risk assessment and patient management. The former RMS for serum apo(a) is no longer available; consequently, an International System of Units (SI)-traceable, ideally multiplexed, and sustainable RMS for apo(a) is needed. METHODS: A mass spectrometry (MS)-based candidate RMP (cRMP) for apo(a) was developed using quantitative bottom-up proteomics targeting 3 proteotypic peptides. The method was provisionally validated according to ISO 15193 using a single human serum based calibrator traceable to the former WHO-IFCC RMS. RESULTS: The quantitation of serum apo(a) was by design independent of its size polymorphism, was linear from 3.8 to 456 nmol/L, and had a lower limit of quantitation for apo(a) of 3.8 nmol/L using peptide LFLEPTQADIALLK. Interpeptide agreement showed Pearson Rs of 0.987 and 0.984 for peptides GISSTVTGR and TPENYPNAGLTR, and method comparison indicated good correspondence (slopes 0.977, 1.033, and 1.085 for LFLEPTQADIALLK, GISSTVTGR, and TPENYPNAGLTR). Average within-laboratory imprecision of the cRMP was 8.9%, 11.9%, and 12.8% for the 3 peptides. CONCLUSIONS: A robust, antibody-independent, MS-based cRMP was developed as higher order RMP and an essential part of the apo(a) traceability chain and future RMS. The cRMP fulfils predefined analytical performance specifications, making it a promising RMP candidate in an SI-traceable MS-based RMS for apo(a).
引用
- Ruhaak LR, Romijn FPHTM, Begcevic Brkovic I, et al. Development of an LC-MRM-MS-Based Candidate Reference Measurement Procedure for Standardization of Serum Apolipoprotein (a) Tests. Clin Chem. 2023. PMID: 36644914. doi:10.1093/clinchem/hvac204
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。